{"id":43852,"date":"2025-10-20T18:46:07","date_gmt":"2025-10-20T10:46:07","guid":{"rendered":"https:\/\/flcube.com\/?p=43852"},"modified":"2025-10-20T18:46:07","modified_gmt":"2025-10-20T10:46:07","slug":"merck-kgaa-secures-nmpa-approval-for-erbitux-in-braf%e2%80%91v600e-mcrc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43852","title":{"rendered":"Merck KGaA Secures NMPA Approval for Erbitux in BRAF\u2011V600E\u202fmCRC"},"content":{"rendered":"\n<p><strong>Merck KGaA<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:ETR\">ETR: MRK<\/a>) announced that the Chinese <strong>National Medical Products Administration (NMPA)<\/strong> has granted marketing approval for a new indication of <strong>Erbitux (Cetuximab Injection)<\/strong>. The approval authorizes the drug in combination with <strong>Braftovi (Encorafenib)<\/strong> for adult patients with <strong>BRAF\u202fV600E mutation\u2011positive metastatic colorectal cancer (mCRC)<\/strong> who have previously received systemic therapy. This marks the fifth indication for Erbitux in China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-supporting-the-approval\">Clinical Evidence Supporting the Approval<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Design<\/th><th>Population<\/th><th>Key Findings<\/th><\/tr><\/thead><tbody><tr><td><strong>BEACON\u202fCRC<\/strong><\/td><td>Randomized, multicenter, Phase\u202fIII<\/td><td>Global mCRC patients<\/td><td>Combination of Erbitux\u202f+\u202fBraftovi increased overall survival vs. standard therapy; 40\u202f% risk\u2011reduction in death<\/td><\/tr><tr><td><strong>NAUTICAL<\/strong><\/td><td>Bridging study in China<\/td><td>Chinese mCRC patients<\/td><td>45\u202f% reduction in risk of death with Erbitux\u202f+\u202fBraftovi vs. control<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Survival Benefit<\/strong> \u2013 The global BEACON study demonstrated a statistically significant overall survival advantage, while the NAUTICAL study confirmed comparable efficacy in the Chinese population.<\/li>\n\n\n\n<li><strong>Safety Profile<\/strong> \u2013 Incidence of adverse events was consistent with the known safety profile of Erbitux and Braftovi, supporting the combination\u2019s tolerability.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-impact-for-merck-kgaa\">Strategic Impact for Merck\u202fKGaA<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Expanded Portfolio<\/strong> \u2013 The new indication strengthens Merck\u202fKGaA\u2019s position in the oncology market, adding a valuable treatment option for a high\u2011risk patient subgroup.<\/li>\n\n\n\n<li><strong>Market Penetration<\/strong> \u2013 With China\u2019s largest oncology patient base, the approval unlocks significant commercial potential.<\/li>\n\n\n\n<li><strong>Pipeline Synergy<\/strong> \u2013 The partnership between Erbitux and Braftovi aligns with Merck\u202fKGaA\u2019s focus on targeted therapies for oncogenic mutations.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck KGaA (ETR: MRK) announced that the Chinese National Medical Products Administration (NMPA) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43853,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[1147,120],"class_list":["post-43852","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-etr-mrk","tag-merck"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck KGaA Secures NMPA Approval for Erbitux in BRAF\u2011V600E\u202fmCRC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck KGaA (ETR: MRK) announced that the Chinese National Medical Products Administration (NMPA) has granted marketing approval for a new indication of Erbitux (Cetuximab Injection). The approval authorizes the drug in combination with Braftovi (Encorafenib) for adult patients with BRAF\u202fV600E mutation\u2011positive metastatic colorectal cancer (mCRC) who have previously received systemic therapy. This marks the fifth indication for Erbitux in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43852\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck KGaA Secures NMPA Approval for Erbitux in BRAF\u2011V600E\u202fmCRC\" \/>\n<meta property=\"og:description\" content=\"Merck KGaA (ETR: MRK) announced that the Chinese National Medical Products Administration (NMPA) has granted marketing approval for a new indication of Erbitux (Cetuximab Injection). The approval authorizes the drug in combination with Braftovi (Encorafenib) for adult patients with BRAF\u202fV600E mutation\u2011positive metastatic colorectal cancer (mCRC) who have previously received systemic therapy. This marks the fifth indication for Erbitux in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43852\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-20T10:46:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2003.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43852#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43852\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck KGaA Secures NMPA Approval for Erbitux in BRAF\u2011V600E\u202fmCRC\",\"datePublished\":\"2025-10-20T10:46:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43852\"},\"wordCount\":260,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43852#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2003.webp\",\"keywords\":[\"ETR: MRK\",\"Merck\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43852#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43852\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43852\",\"name\":\"Merck KGaA Secures NMPA Approval for Erbitux in BRAF\u2011V600E\u202fmCRC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43852#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43852#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2003.webp\",\"datePublished\":\"2025-10-20T10:46:07+00:00\",\"description\":\"Merck KGaA (ETR: MRK) announced that the Chinese National Medical Products Administration (NMPA) has granted marketing approval for a new indication of Erbitux (Cetuximab Injection). The approval authorizes the drug in combination with Braftovi (Encorafenib) for adult patients with BRAF\u202fV600E mutation\u2011positive metastatic colorectal cancer (mCRC) who have previously received systemic therapy. This marks the fifth indication for Erbitux in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43852#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43852\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43852#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2003.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2003.webp\",\"width\":1080,\"height\":608,\"caption\":\"Merck\u202fKGaA Secures NMPA Approval for Erbitux in BRAF\u2011V600E\u202fmCRC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43852#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck KGaA Secures NMPA Approval for Erbitux in BRAF\u2011V600E\u202fmCRC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck KGaA Secures NMPA Approval for Erbitux in BRAF\u2011V600E\u202fmCRC - Insight, China&#039;s Pharmaceutical Industry","description":"Merck KGaA (ETR: MRK) announced that the Chinese National Medical Products Administration (NMPA) has granted marketing approval for a new indication of Erbitux (Cetuximab Injection). The approval authorizes the drug in combination with Braftovi (Encorafenib) for adult patients with BRAF\u202fV600E mutation\u2011positive metastatic colorectal cancer (mCRC) who have previously received systemic therapy. This marks the fifth indication for Erbitux in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43852","og_locale":"en_US","og_type":"article","og_title":"Merck KGaA Secures NMPA Approval for Erbitux in BRAF\u2011V600E\u202fmCRC","og_description":"Merck KGaA (ETR: MRK) announced that the Chinese National Medical Products Administration (NMPA) has granted marketing approval for a new indication of Erbitux (Cetuximab Injection). The approval authorizes the drug in combination with Braftovi (Encorafenib) for adult patients with BRAF\u202fV600E mutation\u2011positive metastatic colorectal cancer (mCRC) who have previously received systemic therapy. This marks the fifth indication for Erbitux in China.","og_url":"https:\/\/flcube.com\/?p=43852","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-20T10:46:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2003.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43852#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43852"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck KGaA Secures NMPA Approval for Erbitux in BRAF\u2011V600E\u202fmCRC","datePublished":"2025-10-20T10:46:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43852"},"wordCount":260,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43852#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2003.webp","keywords":["ETR: MRK","Merck"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43852#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43852","url":"https:\/\/flcube.com\/?p=43852","name":"Merck KGaA Secures NMPA Approval for Erbitux in BRAF\u2011V600E\u202fmCRC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43852#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43852#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2003.webp","datePublished":"2025-10-20T10:46:07+00:00","description":"Merck KGaA (ETR: MRK) announced that the Chinese National Medical Products Administration (NMPA) has granted marketing approval for a new indication of Erbitux (Cetuximab Injection). The approval authorizes the drug in combination with Braftovi (Encorafenib) for adult patients with BRAF\u202fV600E mutation\u2011positive metastatic colorectal cancer (mCRC) who have previously received systemic therapy. This marks the fifth indication for Erbitux in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43852#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43852"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43852#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2003.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2003.webp","width":1080,"height":608,"caption":"Merck\u202fKGaA Secures NMPA Approval for Erbitux in BRAF\u2011V600E\u202fmCRC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43852#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck KGaA Secures NMPA Approval for Erbitux in BRAF\u2011V600E\u202fmCRC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2003.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43852"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43852\/revisions"}],"predecessor-version":[{"id":43854,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43852\/revisions\/43854"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43853"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}